tirzepatide back on shortage list is NO longer in SHORTAGE. What You Need to Know FDA reconsidering its decision to

238 studied genes related to glutaminolysis in order to determine the sensitivity of glutamine metabolism to xCT-targeted therapy in head and neck squamous cell carcinoma

Retatrutide (development code LY3437943) is a synthetic peptide developed by Eli Lilly that acts as an agonist at three distinct receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors

If you're carb counting or using closed-loop insulin delivery, mention to your diabetes care team that you've started a GLP-1 medication so you can adjust your approach if needed

Katsurada K, Maejima Y, Nakata M, Kodaira M, Suyama S, Iwasaki Y, et al

To help minimize these side effects, starting with a lower dosage as directed by your healthcare provider is key